CAPR
Capricor's Deramiocel Navigates FDA Review: A Complex Journey Towards Approval
Capricor's second quarter 2026 earnings call brought some clarity to the regulatory status of its flagship product, deramiocel. The company has been working tirelessly to get this innovative therapy approved by the FDA for the treatment of cardiomyopathy in Duchenne muscular dystrophy (DMD) patients. However, the outcome of